CLEVELAND , Oct. 15, 2025 /PRNewswire/ — Legendary actor and philanthropist William Shatner has joined forces with IdentifySensors Biologics, a pioneer in digital molecular diagnostics, to announce that the company has raised more than $20 million to accelerate the commercialization of Check4 — a breakthrough platform poised to transform how the world detects early cancer and infectious diseases.
Check4 is designed to be the first fully digital, real-time molecular diagnostic system capable of delivering lab-quality results in under five minutes from a simple blood or saliva sample — without PCR, reagents or complex lab infrastructure. The platform leverages graphene-based semiconductors, artificial intelligence-driven algorithms and cloud-powered connectivity to enable accurate, decentralized and affordable diagnostics worldwide.
“We believe this is the future of diagnostics,” Shatner said. “Early cancer detection saves lives. This technology can put that power in the hands of people everywhere, instantly and affordably. I’m proud to be part of this mission.”
Shatner’s involvement underscores a growing movement to make diagnostics accessible beyond hospitals and labs — into clinics, rural health centers, low-resource regions and ultimately into homes worldwide.
Breakthrough Milestone
IdentifySensors recently achieved a landmark validation: the detection of the three key EGFR mutations that drive non-small cell lung cancer (NSCLC) – L858R, Exon 19 deletions and T790M. NSCLC accounts for nearly 85 percent of lung cancer cases and remains the leading cause of cancer death worldwide, making rapid, precise EGFR detection critical for guiding targeted therapies. Testing from model blood samples shows sensitivity down to 50 copies/mL, comparable to FDA-cleared PCR benchmarks, supporting earlier detection and real-time therapy guidance using Check4’s disposable, low-cost cartridges.
Why It Matters
- $20M+ raised to date supporting commercialization
- 26 issued U.S. patents with 10 pending
- Detects cancer and disease without amplification or reagents
- Designed for clinical and at-home use
- FDA submission initiated for infectious disease assays
The Next Chapter: A Call for Partners
The company is now raising an additional $7.1M in a Series A round to validate volume production, initiate expansion into oncology companion diagnostics (CDx), and pursue regulatory clearance for priority infectious disease targets. With Shatner championing the mission, IdentifySensors aims to rally support from celebrities, healthcare leaders, and global changemakers united by the urgent need for affordable, real-time cancer and infectious disease detection.
“Healthcare innovation is not just about technology and clinical effectiveness; it’s about equity, access and saving lives,” said IdentifySensors Biologics CEO Gregory Hummer MD. “With William Shatner’s support, we’re building momentum to make real-time disease and cancer detection the new global standard.”
About IdentifySensors Biologics
IdentifySensors Biologics is a pioneer in digital molecular diagnostics. Its flagship platform, Check4®, eliminates traditional barriers, including reagents, labs and delays, delivering rapid, affordable and lab-quality results through a connected, SaaS-enabled system. Based in Cleveland with R&D facilities in Gainesville, Florida, IdentifySensors is committed to making early detection accessible to everyone, everywhere. For more information, visit www.identifysensors.com, contact John Peroni 440.622.0777, [email protected] and watch William Shatner’s message here: https://youtu.be/TTSrwSJgfcU?si=12DCn7QVND_xrPv4
News Media Contact
Joe Mosbrook
[email protected]
216-375-2141
SOURCE IdentifySensors Biologics
